NCT03421912View on ClinicalTrials.gov

Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)

NACompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 16, 2018

Primary Completion Date

April 11, 2021

Study Completion Date

May 11, 2021

Conditions
Head and Neck Squamous Cell CarcinomaColorectal CancerNon Small Cell Lung CancerEpidermal Growth Factor Receptor Inhibitor
Interventions
OTHER

Cicaplast Balm B5

The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers

OTHER

Dexeryl

The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers

Trial Locations (1)

69008

Centre Léon Bérard, Lyon

All Listed Sponsors
lead

Centre Leon Berard

OTHER

NCT03421912 - Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR) | Biotech Hunter | Biotech Hunter